Objective The sustained virological response (SVR) rate has improved to >70% for patients with hepatitis C virus genotype 1 treated with the triple therapy of telaprevir (TVR), pegylated interferon (PEG-IFN)-α, and ribavirin (RBV). However, this therapy has various adverse effects, although there have been no reports of it decreasing body weight. Methods A total of 175 patients with chronic hepatitis C received one of three IFN-based regimens (35 received the PEG-IFN/RBV/TVR (PRT) regimen, 70 received the PEG-IFN/RBV (PR) regimen, and 70 received the IFN-β/RBV (FR) regimen) and body weight was followed for 12 weeks. Resuts Decreases in body weight up to week 12 were significantly greater in the PRT group than in the PR or FR groups (p<0.001). The proportion of patients who experienced weight loss ! 5.0 kg by week 12 in the PRT group was significantly higher than in the PR or FR groups (p<0.001) regardless of baseline ghrelin level. The question 18 score (appetite) of the Beck Depression Inventory-II at week 12 was significantly higher in the PRT group than in the PR or FR groups (p<0.001). A multivariate analysis revealed PRT, the ghrelin level before treatment (<7.0 fmol/mL), and the question 18 score in week 12 (2 or 3) to be independent factors associated with a decrease in body weight ! 5.0 kg from week 0 to week 12. Conclusion PEG-IFN/RBV/TVR therapy yielded high SVR rates, but it was associated with a decreased body weight due to TVR-induced appetite loss.
Introduction
Although pegylated interferon plus ribavirin (PEG-IFN/ RBV) combination therapy has been used during the past decade as a form of IFN-based therapy for chronic hepatitis C virus (HCV), sustained virological response (SVR) rates of approximately 40-50% have been reported among patients with HCV genotype 1 (1) (2) (3) . Telaprevir (TVR)-based triple therapy (PEG-IFN/RBV/TVR), in which TVR is added to PEG-IFN/RBV therapy, is now commonly used. This triple therapy has resulted in improved SVR rates of ! 70% among patients with HCV genotype 1 and it is now considered to be a first-line therapy. However, this therapy has also been associated with many serious adverse effects (4) .
A decreased body weight during IFN therapy influences PEG-IFN and RBV doses and can contribute to treatment discontinuation due to general malaise. There have been reported cases of a decreased body weight during PEG-IFN/ RBV therapy (5) . The onset of depression symptoms has also been observed during PEG-IFN/RBV therapy (6) . Therefore, PEG-IFN may be associated with a decreased body weight due to the onset of depression symptoms; however, PEG-IFN/RBV/TVR therapy is associated with greater decreases in body weight. Interferon-β plus RBV (IFN-β/ RBV) therapy has a low association with the onset of depression symptoms and it is a safe treatment that can be administered to elderly patients (6, 7) .
Ghrelin, a peptide hormone that is produced by the stom-ach, stimulates growth hormone secretion by acting on the pituitary gland and appetite by acting on the hypothalamus (8) . Patients with functional dyspepsia presenting with loss of appetite show low plasma ghrelin levels (9) . Furthermore, an association between loss of appetite and the plasma ghrelin levels during cisplatin treatment has been reported (10) . Although the adverse effects of PEG-IFN/RBV/ TVR include decreased body weight, no studies have investigated the relationship between this triple therapy and decreased body weight. We herein describe our efforts to investigate PEG-IFN/ RBV/TVR therapy compared with PEG-IFN/RBV or IFN-β/ RBV therapy to determine whether decreased body weight during PEG-IFN/RBV/TVR therapy is due to TVR-induced loss of appetite based on pre-treatment plasma ghrelin levels and intra-treatment Beck Depression Inventory-II (BDI-II) scores.
Materials and Methods

Study patients
Between January 2005 and June 2013, 905 patients with hepatitis C received RBV-containing IFN therapy at the Shin-Kokura Hospital and Kitakyushu Municipal Medical Center, including 717 patients who received the PEG-IFN/ RBV regimen, 141 patients who received the IFN-β/RBV regimen, and 47 patients who received the PEG-IFN/RBV/ TVR regimen.
All patients gave their informed consent before participating in this trial. Among the patients eligible to start IFN therapy on an inpatient basis, only those who gave their informed consent for this study were included. For inclusion, patients were also required to be available for pre-treatment determination of plasma ghrelin levels and BDI-II testing. Before November 2011, the patients were prescribed either the PEG-IFN/RBV or IFNβ/RBV regimen by their primary physicians. Patients taking sleep-inducing drugs or antidepressants were prescribed the IFNβ/RBV regimen. After November 2011, patients with the HCV genotype 1 and a high viral load were prescribed the PEG-IFN/RBV/TVR regimen. All enrolled patients had the HCV genotype 1b and a high viral load (HCV RNA levels " 5.0 log IU/mL). The patients were assigned to one of the following three groups: (1) the PEG-IFN/RBV/TVR (PRT) group, consisting of 35 patients who received PRT therapy for 24 weeks; (2) the PEG-IFN/ RBV (PR) group, consisting of 70 patients who received PR therapy for 48 weeks; and (3) the IFN-β/RBV (FR) group, consisting of 70 patients who received FR therapy for 48 weeks. This study was a prospective, non-randomized, open trial.
The study protocol complied with the Good Clinical Practice Guidelines and the 1975 Declaration of Helsinki and was approved by the institutional review board.
Exclusion criteria were as follows: (i) clinical or biochemical evidence of hepatic decompensation or advanced cirrhosis identified by ascites, encephalopathy, or hepatocellular carcinoma; (ii) adherence to specific laboratory parameters (PEG-IFN/RBV/TVR, a white blood cell count < 4×10 9 /L, platelet count <80×10 9 /L, hemoglobin level <120 g/L; PEG-IFN/RBV, white blood cell count <4×10 9 /L and platelet count <80×10 9 /L; IFN-β/RBV, white blood cell count <3×10 9 /L and platelet count <50×10 9 /L); (iii) concomitant liver disease other than hepatitis C (hepatitis B surface antigen or human immunodeficiency virus positive); (iv) excessive active alcohol consumption >60 g per day or drug abuse; (v) severe psychiatric disease; (vi) antiviral or corticosteroid therapy in the 12 months prior to enrollment; (vii) current, or history of, gastric cancer, gastric ulcer, or duodenal ulcer as evidenced on gastroscopy at baseline; and (ix) baseline total BDI-II scores " 10.
IFN treatment
PRT triple therapy
Patients received combination treatment with TVR (Telavic; Mitsubishi Tanabe Pharma, Osaka, Japan), PEG-IFNα2b (PEG-Intron; MSD, Tokyo, Japan), and RBV (Rebetol; MSD) for 12 weeks, followed by an additional 12 weeks of PEG-IFN-α2b and RBV alone. TVR (750 mg) was administered three times a day at 8-hr intervals after each meal (2,250 mg per day). PEG-IFN-α2b was injected subcutaneously once weekly at a dose of 1.5 μg kg -1 . RBV was given orally at a daily dose of 600-1,000 mg based on body weight (600 mg for patients weighing <60 kg, 800 mg for those weighing 60-80 kg, and 1,000 mg for those weighing >80 kg). The above durations and dosages are those approved by the Japanese Ministry of Health, Labor and Welfare.
PR combination therapy PR combination therapy consisted of the subcutaneous injection of PEG-IFNα-2b at a median dose of 1.5 μg/kg once a week. The RBV dose was adjusted according to body weight (600 mg for those ! 60 kg; 800 mg for those >60 but ! 80 kg; and 1,000 mg for those >80 kg) based on the guidelines of the Ministry of Health, Labour and Welfare of Japan.
IFN-β/RBV combination therapy FR combination therapy consisted of the intravenous administration of IFN-β (Feron; Toray Industries Inc., Tokyo, Japan) at a dose of 6 million units (MU) daily for 4 weeks, followed by 3 times a week for 44 weeks. RBV was administered twice a day according to body weight as described above for the PR combination therapy.
Patients were considered to have a SVR if HCV RNA remained undetectable at 24 weeks after the completion of treatment.
Measurement of ghrelin
Plasma samples were collected before breakfast and promptly centrifuged at 40°C, and the supernatants were acidified with 1 mol/L HCl (1/10 volume). The ghrelin levels were determined by using an Active Ghrelin Enzyme- Linked Immunoassay Kit (Mitsubishi Kagaku Latron, Inc., Tokyo, Japan). Patients with a baseline ghrelin level <7.0 fmol/mL were designated as the low ghrelin group (LG group), while those with a baseline ghrelin level " 7.0 fmol/mL were designated as the high ghrelin group (HG group).
Questionnaire
A questionnaire was conducted immediately before the start of treatment and at 4 and 12 weeks using the BDI-II (11). The questionnaire was administered by a single expert investigator who remained blinded to the patients' treatment regimens, treatment timing, and other information. Patients with a BDI-II score " 14 were considered to have depression symptoms. Additionally, at 4 and 12 weeks, BDI-II Question 18 (appetite) was modified and quantified as follows: 1) no change in appetite from baseline (0); 2) slightly decreased appetite compared with baseline (1); 3) markedly decreased appetite compared with baseline (2); and 4) complete loss of appetite (3). Patients with a Q18 score ! 1 at 12 weeks were designated as the low Q18 group; those with a Q18 score 2 or 3 at 12 weeks were designated as the high Q18 group.
The blood chemistry, urinalysis, and HCV RNA level measurements were performed in all patients every 4 weeks from the start of IFN treatment to 24 weeks after the end of treatment. All patients were weighed at baseline and again at week 12.
Statistical analysis
Statistical analyses were performed using the PASW Statistics version 18 and R version 2.11. Categorical data were analyzed using the Chi-squared test and Fisher's exact test, and continuous data were analyzed using the nonparametric Mann-Whitney U-test. Univariate and multivariate logistic regression analyses were used to determine those factors that significantly contributed to decreased body weight >5.0 kg from week 0 through week 12. The odds ratios (OR) and 95% confidence intervals (95% CI) were also calculated. A two-tailed p value <0.05 was considered significant. Age, gender, body weight before IFN treatment, the method of IFN treatment, efficacy of IFN treatment, the pretreatment ghrelin level, BDI-II Question 18 score, and total BDI-II score were entered into a multiple logistic regression analysis to identify any significant independent predictive factors associated with decreases in body weight >5.0 kg from week 0 through week 12.
Results
Patient demographic information
Patient age, sex, and baseline body weight were well balanced among the treatment groups (Table 1) . No differences in baseline hemoglobin level, platelet count, alanine aminotransferase (ALT), γ-glutamyl transpeptidase (γ-GTP), HCV RNA level, or plasma ghrelin level were found among the treatment groups.
Changes in body weight at week 12 of IFN treatment by assessing the baseline plasma ghrelin levels
The PRT and PR groups showed decreases in body weight of 6.7 and 4.1 kg, respectively, whereas the FR group showed an increase in body weight of 1.4 kg (Table 2). Thus, the PRT group showed a decrease in body weight that was significantly greater than observed in the PR or FR group (p<0.001). Among the patients with a baseline plasma ghrelin level <7.0 fmol/mL (the LG group), both the PRT and PR groups showed a decrease in body weight with no significant treatment difference. However, as no decrease in body weight was observed in the FR group, both the PRT and PR groups showed decreases in body weight that were significantly greater than observed in the FR group (p<0.01). Among the patients with a baseline plasma ghrelin level " 7.0 fmol/mL (the HG group), the PRT group showed a significantly greater decrease in body weight than observed in the PR and FR groups (p<0.001).
Changes over time in total and Q18 BDI-II scores
The BDI-II total score at week 12 was significantly higher in the PRT group than in the PR or FR group (p< 0.05 and p<0.01, respectively)( Table 3 ). The total BDI-II score in the PR group was significantly higher than in the FR group (p<0.01). The onset of depression symptoms during IFN therapy was less common in the FR group than in any IFN-based therapy group. The Q18 scores at weeks 4 and 12 were significantly higher in the PRT group than in the PR and FR groups (p<0.001 and p<0.001, respectively). The Q18 scores at weeks 4 and 12 did not differ between the PR and FR groups. Loss of appetite during PRT therapy was believed to be due to TVR.
Proportion of patients with decreases in body weight ! 5.0 kg from week 0 to week 12 (PDBW5)
Sixty-three of the 175 subjects (36%) experienced a decrease in body weight ! 5 kg up to week 12 of treatment ( Table 4) .
The proportion of patients who experienced decreases in body weight ! 5.0 kg (the PDBW5) in the PRT group (89%) was significantly higher than in the PR (40%) or FR (6%) groups (p<0.001).
Among the patients in the LG group, the PRT and PR groups showed a higher PDBW5 with no treatment differences. A lower PDBW5 was seen in the FR group, and both the PRT and PR groups showed a significantly higher PDBW5 than seen in the FR group (p<0.001). Among the patients in the HG group, the PDBW5 in the PRT group (91%) was significantly higher than in the PR or FR group (p<0.001). As the PRT group had a higher PDBW5 regardless of the ghrelin level and the FR group had a lower PDBW5 regardless of the ghrelin level, there was no difference in the ghrelin levels among the treatment groups. Of the three treatment groups, only the PR group had a significantly different PDBW5 between the patient groups stratified based on the baseline ghrelin level (p<0.001).
When analyzing the BDI-II total score at week 12, the PDBW5 among the patients with a total score ! 14 was significantly higher than observed among the patients with a total score <14 (p<0.001). In the PRT and PR groups, however, no difference was found in the PDBW5 among the patient groups stratified based on the BDI-II total score at week 12, thus indicating no effect of the onset of depression symptoms on the decrease in body weight.
The percentage of patients with a BDI-II total score ! 14 did not differ between the PRT and PR groups. The FR group had a significantly lower percentage of patients with a BDI-II total score ! 14 (9%) than the PRT (31%) or PR (30%) groups (p<0.01). The onset of depression symptoms was observed in approximately 30% of the patients in the PRT or PR groups, while the FR group had a lower incidence of depression symptom onset during treatment.
According to the Q18 score at week 12, the PDBW5 among the patients in the high Q18 score group was significantly higher than observed among the patients in the low Q18 score group (p<0.001). Decreases in body weight were likely due to decreased food consumption associated with a loss of appetite. The PRT group had a significantly higher percentage of patients designated as the high Q18 group (37%; 13/35 patients) than the PR (14%; 10/70 patients) or FR (4%; 3/70 patients) groups (p<0.01 and p<0.001, respec- tively). The PR group had a significantly higher percentage of patients designated as being in the high Q18 group than in the FR group (p<0.05). Patients receiving the PRT therapy had the most frequent incidence of appetite loss during treatment and the largest decrease in body weight, thus indicating a marked TVR-associated loss of appetite.
Results of multivariate logistic regression analyses of the factors associated with a decrease in body weight ! 5.0 kg from week 0 to week 12
Significant predictive factors associated with a decrease in body weight ! 5.0 kg from week 0 to week 12 included the method of IFN therapy (PRT), the plasma ghrelin level before treatment (<7.0 fmol/mL), and the Q18 score at week 12 (2 or 3) (Table 5 ).
Response to IFN therapy and discontinuation
A total of 91% of patients (32/35 patients) achieved SVR following IFN-based therapy with PRT, 53% (37/70 patients) after PR therapy, and 36% (25/70 patients) after FR therapy. The SVR rate after PRT therapy was significantly higher than after PR or FR therapy (p<0.0001).
Seven patients (20%) in the PRT group discontinued treatment after week 12 due to anemia (three patients), general malaise (three patients), or pneumonia (one patient). All of the patients who discontinued treatment experienced a decrease in body weight ! 5.0 kg up to week 12. Eight patients (11%) in the PR group discontinued treatment due to anemia (three patients), general malaise (three patients), depression symptoms (one patient), or thyroid dysfunction (one patient). One patient in the FR group discontinued treatment due to proteinuria. The percentage of patients who discontinued treatment in the FR group was significantly lower than in the PRT or PR group (p<0.001 and p<0.05, respectively).
Discussion
PEG-IFN/RBV therapy was introduced in December 2004
and became the most commonly used form of IFN therapy. In November 2011, PEG-IFN/RBV/TVR therapy, with improved therapeutic effects, was introduced for patients with HCV genotype 1 and a high viral load, after which PEG-IFN/RBV/TVR therapy became the main form of IFN therapy in patients with HCV genotype 1 and a high viral load. However, this triple therapy has also been associated with many adverse effects (4), a including decreased body weight during treatment, although there have so far been no studies investigating a decreased body weight during the triple therapy. In the present study, we found evidence of the occurrence of a decreased body weight due to TVR-induced loss of appetite. We also found that such a decreased body weight occurred regardless of the baseline ghrelin levels. Seven patients experiencing a decrease in body weight ! 5.0 kg up to week 12 discontinued treatment after week 12, thus suggesting that a decreased body weight after the start of treatment was an important factor for treatment completion.
There have also been reported cases of a decreased body weight during PEG-IFN/RBV therapy (5) . In the present study, a mean decrease of 4.1 kg in body weight was observed during PEG-IFN/RBV therapy, and approximately 40% of those patients experienced a decrease in body weight ! 5.0 kg up to week 12. Furthermore, the patients receiving PEG-IFN/RBV therapy are more likely to be in a depressive state than those receiving IFN-β/RBV therapy (6) . In the present study, the percentage of patients with a total BDI-II score ! 14 at week 12 was significantly higher in the PEG-IFN/RBV group (30%) than in the IFN-β/RBV group (9%). However, no association was found between decreases in body weight ! 5.0 kg up to week 12 and BDI-II total scores in the PEG-IFN/RBV group, suggesting no association between decreases in body weight during PEG-IFN/RBV therapy and depression symptoms.
There have been reported cases of decreased plasma ghrelin levels during PEG-IFN/RBV therapy (12) . The present study did not evaluate the potential associations between patients with decreased body weight and the on-treatment ghrelin levels because the on-treatment ghrelin levels were not obtained during the study. However, during PEG-IFN/ RBV therapy, more patients in the group with lower baseline plasma ghrelin levels experienced a decreased body weight compared with the patients in the group with higher baseline plasma ghrelin levels. With PEG-IFN/RBV therapy, the baseline ghrelin level appeared to be an important factor contributing to a decreased body weight during treatment.
IFN-β/RBV therapy has been used as a form of IFNbased therapy in elderly or depressed patients with HCV (6, 7) . In the present study, IFN-β/RBV therapy had a low association with a decreased body weight and depression symptom onset, it was discontinued in fewer patients, and, therefore, appears to be a safe treatment regimen. However, since the SVR rate among patients with HCV genotype 1 receiving IFN-β/RBV therapy was lower than observed in patients receiving PEG-IFN/RBV/TVR therapy, the use of IFN-β/RBV therapy is recommended in elderly or depressed patients.
The observed decreases in body weight during PEG-IFN/ RBV/TVR therapy were significantly greater than those during PEG-IFN/RBV or IFN-β/RBV therapy regardless of the baseline plasma ghrelin level. The cause of TVR-induced loss of appetite is unknown. A severe loss of appetite occurred early during treatment with TVR. Although a loss of appetite occurred during treatment with PEG-IFN, it was more frequent in patients with low baseline ghrelin levels (i.e., those with a loss of appetite). As the TVR-induced loss of appetite was extreme, most patients treated with TVR therefore tend to experience a loss of appetite, regardless of their baseline level of appetite. In thus appears that a loss of appetite occurred irrespective of the baseline ghrelin level. Starting at week 4 of treatment, the Q18 score was higher in the PEG-IFN/RBV/TVR group than in the PEG-IFN/RBV group, thus suggesting the occurrence of a loss of appetite associated with TVR early in treatment. A significantly greater number of patients receiving PEG-IFN/RBV/TVR therapy than those receiving PEG-IFN/RBV or IFN-β/RBV therapy experienced a severe loss of appetite (Q18 score 2 or 3). Patients with a severe loss of appetite (Q18 score 2 or 3) were more likely to experience a decreased body weight, suggesting that a decreased body weight following PEG-IFN/RBV/TVR therapy was due to a severe TVR-induced loss of appetite. No association was found between a decreased body weight during PEG-IFN/RBV/TVR or PEG-IFN/RBV therapy and the onset of depression symptoms, suggesting that a decreased body weight was not due to depression symptoms. Multivariate analyses identified PEG-IFN/RBV/TVR therapy, the baseline plasma ghrelin level, and the Q18 score at week 12 as significant independent factors for a decreased body weight. These findings suggests that a decreased body weight during PEG-IFN/RBV/TVR therapy is due to a TVR-associated loss of appetite.
Conclusion
PEG-IFN/RBV/TVR therapy is highly effective, but it is often discontinued even after week 12 of treatment due to general malaise, due to patients experiencing a decreased body weight by this stage or other adverse effects. Therefore, critical surveillance of a loss of appetite or a decreased body weight and a proper response is necessary when treating such patients.
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